How big is the Cell Therapy CDMO Market?
According to 6Wresearch internal database and industry insights, the cell therapy CDMO (Contract Development and Manufacturing Organization) market was valued at approximately USD 2.8 billion in 2024 and is projected to reach USD 7.4 billion by 2031, growing at a CAGR of 14.2% during the forecast period.
This growth is driven by the surge in cell and gene therapy pipelines, high demand for GMP-compliant manufacturing support, and outsourcing preferences among biotech firms.
Key Growth Drivers of the Cell Therapy CDMO Market
- Increasing volume of CAR-T, TCR-T, and stem cell therapy clinical trials
- High capital investment required for in-house GMP facilities
- Expertise demands for complex scaling, vector production, and cell expansion
- Rising collaboration between biotech innovators and CDMO providers
- Regulatory emphasis on quality, traceability, and process validation
Cell Therapy CDMO Market Trends
Cell therapy CDMO market is moving toward vertically integrated service offerings encompassing development, regulatory support, analytics, and commercial-scale manufacturing. Outsourcing strategic alliances are being established to co-develop proprietary platforms and streamline technology transfer. Single-use bioprocessing systems and closed-vessel automation are gaining prominence to reduce contamination risks and improve batch consistency. Providers are also offering modular fill finish and logistics services to support global distribution of therapies.
Emerging Developments in the Cell Therapy CDMO Market
The new advances would involve the use of AI-based digital twins toward the maximization of production output and process management. There are multi-product manufacturing sites being established to produce pipeline mix of autologous and allogeneic products. Chain-of-identity solutions based on blockchain blockchain-based batch certification are in pilot phase. Spatial bioreactors allowing real-time monitoring and scalability are being presented. Besides, CDMOs are teaming up with technology firms to come up with decentralized GMP pods that can produce cell therapy products at point of care.
Major Companies in the Cell Therapy CDMO Market
- Lonza Group
- Thermo Fisher Scientific
- Catalent, Inc.
- WuXi AppTec
- Samsung Biologics
- AGC Biologics
- Cytiva (Danaher)
- Miltenyi Biotec
- Oxford Biomedica
- Fujifilm Diosynth Biotechnologies
How Big Is the Cell Therapy CDMO Market : FAQ's
The market was valued at USD 2.8 billion in 2024 and is projected to reach USD 7.4 billion by 2031 at a CAGR of 14.2%.
Specialized GMP expertise, cost efficiency, capacity scaling, and regulatory support.
CAR-T, stem cell, and gene-modified T-cell therapies dominate CDMO workload.
Manufacturing complexity, supply chain coordination, and facility capacity constraints.
6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.
Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on
sales@6wresearch.com